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Abstract  
The shortage of donors to face the increasing number of patients listed for renal 
transplantation has prompted several strategies including the use of kidneys with a 
tumor, whether occasionally found on harvesting from a deceased donor or 
intentionally removed from a living donor and transplanted after excision of the 
lesion. Current evidence suggests that a solitary well-differentiated RCC, Fuhrman 
nuclear grade I-II, less than 1 cm in diameter and resected before grafting may be 
considered at minimal risk of recurrence in the recipients who should however be 
informed of the possible risk and should consent to receive that graft. 
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Introduction 
 
At present, renal transplantation is the best treatment available for patients with 
End-Stage Renal Disease (ESRD) being a current practice in industrialized countries 
thanks to the significant improvements in immunosuppressive and supportive 
therapy which have occurred in the last years.  
However, while the number of patients listed to receive a kidney from a deceased 
donor is progressively increasing, donor numbers have remained stable in recent 
years leading to larger waiting lists and longer waiting time to receive a kidney.  
Several strategies have been used to face the shortage of donors, including 
transplantation of kidneys from “extended criteria donors”, transplantation from 
living donors whether related or not, paired living donation from exchanging donors 
to overcome donor-recipient incompatibility, sometimes within a chain of “domino 
transplantation” starting from an altruistic donation (1).   
In this setting, with the aim of transplanting the largest number possible of available 
kidneys, even organs with a renal mass have been considered for grafting.  
 
Safety of grafting kidneys with tumors 
 
Whether a kidney with a tumor should be transplanted is still a matter for 
discussion. While the Kidney Disease Improving Outcome (KDIGO) guidelines do 
not address evaluation of kidney donors (2), the European Best Practice Guidelines 
(EBPG) discourage the acceptance of donors with malignancies (3). On the other 
hand, the guidelines of the European Association of Urology (EAU) suggest that 
kidneys with a small RCC may be transplanted after excision of the lesion (4). 
Transplantation of kidneys with a tumor includes the possibility of transplanting 
organs with a small lesion found during the donation procedure or even kidneys 
removed due to the presence of a renal mass. This last option was proposed for 
patients at higher risk, who accept these grafts, provided that surgery spares enough 
renal tissue to allow the recipient good renal function (5-9). 
This proposal rests on the observation that RCCs show great variability in their 
biological aggressiveness and only 20% of small tumors, i.e. less than 2 cm in 
diameter, are potentially aggressive (10) with a 1-2% incidence of metastatic 
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progression within 2-3 years from diagnosis (11). The proposal was further 
supported by the good oncological outcome reported in patients that underwent 
partial nephrectomy for a solitary, small renal mass, generally smaller than 4 cm in 
major axis, compared to patients who underwent radical nephrectomy (12-14).  
Although complications such as perinephric hematoma or calyceal fistula have 
been reported more frequently after partial nephrectomy, this procedure is largely 
used with the aim of preserving renal function, particularly when one considers that 
nowadays patients tend to be older and have several co-morbidities so that at 
diagnosis approximately one third of them already have a reduced renal function 
(15). Since this approach has brought oncologic outcomes equivalent to radical 
nephrectomy when treating small and limited RCCs (16), the American Urologic 
Association Guidelines strongly recommend the approach as the reference standard 
of care (17). 
Clearly, transplantation of kidneys discarded because of a renal tumor raises 
some ethical concerns: many believe it unethical to refer subjects with small renal 
tumors to transplant centers where the removed kidney may be transplanted after 
excision of the lesion (9). Such treatment is not optimal for the patient and entails a 
clear conflict of interest, unless the subject had already decided to donate a kidney 
and the renal cancer was incidentally discovered during medical evaluation for 
donation.   
For both options considered, the discussion focuses on safety for the recipients, 
given the increased incidence of cancer in transplanted patients, as well as on the 
kidney’s residual function. 
The progressive increase in donor age implies a higher risk of unintended 
transmission of malignancies and a prominent role of RCCs. This tumor was the 
donor-derived malignancy most frequently reported to the Organ Procurement and 
Transplantation Network (OPTN) between 2005 and 2009, accounting for 43.8% of 
all malignancy reports (18). Seven out of 64 potential donor-derived RCCs reported 
to the OPTN were confirmed as being transmitted along with the transplanted 
kidney and one recipients died because of the transmitted malignancy (18). Similar 
results were reported by the Spanish National Transplant Organization Tumor 
registry (19) where again kidney tumors were the most frequently observed in 
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donors, accounting for 47% of cases with cancer, subsequently transmitted to two 
recipients.  
However, the cases reported (table I), indicate that the recurrence rate of small renal 
cancer is low, provided the lesion is completely removed.  
Several years ago, Penn first focused attention on the problem by reporting a 
series of 30 patients transplanted from donors with a renal mass. In 14 cases the 
mass, found upon harvesting, was radically removed without any recurrence in the 
recipient; in 2 cases where the lesion was only partially removed (R1 margins) the 
recipients experienced tumor recurrence and metastasis, thus underlining the 
importance of  radical excision of the lesion before grafting. The remaining 14 
patients received a kidney from donors in whom the opposite kidney had a 
malignancy: only one possible tumor recurrence occurred when a carcinoma was 
found during histological examination of the graft removed for rejection (20). 
However, in a more recent paper Buell reported that 43 out of 70 (61%) donors with 
RCC recorded in the Israel Penn International Transplant Tumor Registry (IPITTR) 
resulted in malignancy transmission to the recipients, with a 15% patient mortality 
(21). 
Nicol described a series of 43 patients intentionally transplanted with kidneys 
discarded because of a mass during a 13 year period, where a new tumor developed 
in only one patient, 9 years after grafting, leaving it open to question whether this 
was a real recurrence or a “de novo” cancer, not only for the length of time from 
grafting but also because the new lesion was far from the previous resection (9). 
These results suggest that, with due caution, kidneys with small tumors may be 
used for transplantation into patients who accept the risk, offering them a chance to 
improve their quality of life and, hopefully, survive longer than on dialysis treatment 
(22).  
 
Relevance of pathological diagnosis 
Accurate pathological diagnosis of the lesion is of the utmost importance when 
deciding whether to transplant a kidney from a donor with a renal mass, as 
suggested by the observation that in the Penn series 7 out of 17 patients who 
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received kidneys with a non-diagnosed renal mass developed metastases 12 months 
after transplantation (20).  
Although clear cell carcinoma accounts for the majority of renal tumors, several 
other entities have recently been added to the traditional classification (23, 24) or are 
under discussion (table II), further emphasizing the need for a proper diagnosis in 
order to assess the risk of tumor transmission and recurrence in the recipient.  
In this setting, tissue processing and the techniques used are of course important. 
The value of frozen section examination to evaluate the margins of the renal mass 
during surgery is debatable. While Penn (25) stressed its utility, Algaba (26) 
reported 20% to 37% false negative results due to incorrect sampling of the lesion, 
particularly when only some fragments are sent to the pathologist who cannot carry 
out a gross examination of the whole lesion which is often crucial for diagnosis.  
Necrosis, fibrosis and/or a cystic tumor component raises the percentage of false 
negative results in fragmentary samples (27-29). Moreover, in frozen tissue the 
cytology and sometimes the architecture too may not be well preserved so that a 
specific diagnostic feature, clearly appreciable on paraffin sections, may not be 
evident on frozen sections. Thus, for example, the classic RCC in a frozen section 
appears as a lesion with large eosinophylic cytoplasm, because the well-known 
"clear cell cytology" is an artifact of routine processing dissolving the glycogen 
contained in the cytoplasm. A variable percentage of false positive cases has also 
been reported, ranging from null to 34% (27), primarily due to misinterpretation of 
crushed renal tubules as a renal neoplasm (30). Again, the exact cytological 
nucleolar grade may be puzzling, due to the nuclear/nucleolar artifacts. However, 
intraoperative frozen section examination may be useful in determining the status of 
the margins in partial nephrectomies (26), provided the pathologist receives the 
entire lesion and not only small fragments, avoiding crush artifacts due to 
diathermocoagulation. 
When appropriate, immunohistochemistry should be used to define the diagnosis,  
as indeed for the differential diagnosis between oncocytoma and chromophobe renal 
cell carcinoma.  
Recent observations suggest that even kidneys with multiple low-grade tumors may 
be suitable for transplantation, provided this condition does not influence the 
Tx K tumors - pag. 7 
functionality of the residual parenchyma. The presence of multiple/miliary nodules 
may in fact compress the parenchyma, creating extensive fibrosis and global 
glomerular sclerosis, or multifocality may herald a hereditary renal neoplastic 
syndrome (31). 
 
Current view 
The Disease Transmission Advisory Committee (DTAC) of the Organ 
Procurement and Transplantation Network/United Network for Organ Sharing 
(OPTN/UNOS) of the United States suggests that solitary well-differentiated RCCs, 
Fuhrnam nuclear grade I-II, less than 1 cm in diameter and resected before grafting, 
may be considered at minimal risk of recurrence in recipients (32). Solitary well-
differentiated RCCs 1 to 2.5 cm in diameter should be considered at low risk and 
still used for transplantation, although only in selected patients whose clinical risk 
while on dialysis treatment outweighs being transplanted with such a graft (table III). 
However, extreme caution should be used when examining data on renal 
transplantation from donors with renal tumors, since most of the cases reported 
(table I) were transplanted from living donors, thus presumably investigated more 
accurately than is usually possible when transplanting a graft from a deceased donor, 
where only a short time is available for the donation procedure. In addition, all cases 
included in the registries were voluntary reported, raising the possibility that they 
may not represent the real risk of tumor transmission. Finally, the small dimension 
of a RCC does not always make it risk-free, since small tumors may be multifocal 
(33), nor is it a guarantee of good prognosis, considering that 7% may cause 
metastases despite the small dimension of tumor (34) and need to be checked for in 
a potential donor. 
With all these caveats in mind, a donor with a low-grade renal cell cancer may be 
considered at standard risk of disease transmission to the recipient (35), who should 
be informed of the possible risk and should consent to receive the graft.    
Finally, although renal transplantation has been proved to be a better treatment than 
dialysis, the pros and cons of the two treatment modalities should be carefully 
weighed when facing decisions carrying even slightly increased risks, and the 
clinical situation of each single patient needs to be assessed.   
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Table I. Reported cases of transplantation of kidneys with tumors.   
OPTN/UNOS = Organ Procurement and Transplantation Network/United Network for Organ Sharing 
LD = Living Donor; RCC = renal cell carcinoma; AML = angiomyolipoma; ONC = oncocytoma; KC = kidney cancer; CC = 
complex cyst 
 
 
author/year (ref) cases 
(n) 
tumor transmission 
to recipient (n) 
recipient death due 
to transmission 
notes 
Ison MG, 2011 (18) 64 7 1 data from OPTN/UNOS registry 
Sener A, 2009 (5) 5 0 0 3 RCC, 2 AML; all LD 
Garrido G, 2008 (19) 55 2 0 data from Spanish National Transplant 
Organization Tumor registry 
Mannami M, 2008 (6) 8 0 0 all RCC, Tx from LD 
Nicol DL, 2008 (9) 43 1 0 38 LD; 3 AML; 4 ONC; 31 KC; 3 CC  
Buell JF, 2004 (21) 70 43 15% data from Israel Penn International 
Transplant Tumor Registry 
Penn I, 1995 (20) 30 3 2 recurrence in 2 cases with partial removal of 
tumor and in 1 out of 14 pts who received a 
contralateral kidney from a RCC donor 
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Table II. Classification of renal neoplasms (ESRD = End Stage Renal Disease) 
 
 
Historical classification (ref 23)  
Clear cell renal carcinoma (CCR) 70% of renal tumors; multifocal 4%; 
bilateral 0.5-3% 
Papillary cell renal carcinoma (PRCC)  
Renal cell carcinoma cromophobe cell type 5% of renal tumors 
Oncocytoma benign; differential diagnosis with the 
eosinophilic variant of Chromophobe 
RCC or CCR 
Collecting duct carcinoma < 1% renal carcinoma 
Renal medullary carcinoma children and pts with sickle cell disease 
Mucinous tubular spindle cell RCC female preponderance 
Angiomyolipoma benign lesion, multifocal in 20% of 
cases; the epithelioid variant is 
malignant 
New proposed entities (ref 24)  
Tubulo-cystic RCC rare 
Acquired cystic disease RCC patients with ESRD; multifocal (50%); 
bilateral (20%) 
Clear cell tubulo-papillary RCC 1% of renal cancers 
MiT family translocation RCC  
Hereditary leiomyomatosis RCC autosomal dominant syndrome 
Rare entities under discussion (ref 24)  
Thyroid-like follicular neoplasia  
Succinate-dehydrogenase B mutation 
associated RCC 
 
ALK translocation RCC  
 
  
Tx K tumors - pag. 15 
Table III. Risk of donor transmission of renal neoplasms to graft recipients (modified 
from ref 32) 
 
Risk of 
transmission 
Tumor Transplant 
Minimal  
(< 0.1%) 
Solitary RCC < 1 cm, well 
differentiated (Fuhrman 1-2) 
yes with informed consent 
Low  
(0.1-1%) 
Solitary RCC 1-2.5 cm, well 
differentiated (Fuhrman 1-2) 
only in patients at risk if not 
transplanted - informed 
consent required 
Intermediate  
(1-10%) 
Solitary RCC  T1b 4-7 cm, well 
differentiated (Fuhrman 1-2) 
not recommended 
High  
(> 10%) 
RCC > 7 cm or stage II-IV to avoid 
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